|Day Low/High||69.17 / 70.91|
|52 Wk Low/High||67.53 / 95.93|
Trade-Ideas LLC identified Perrigo (PRGO) as a post-market leader candidate
The proposal came before former Perrigo boss Papa was installed at the helm of the troubled drugs maker.
Former Tyco International executive Sam Eldessouky will take on the role of controller at the the embattled pharmaceutical company at the end of the month.
Valeant is working to rebrand itself and it's starting with paying CEO Joe Papa less than his predecessor.
Newly appointed CEO Joseph Papa says at the UBS Global Healthcare Conference that the drugmaker will look to pare its debt load through divestitures.
As the pharma company's investors remain in "show me mode" with a new CEO at the helm, its maintained guidance may have offset revised earning results.
Doug Kass shares his thoughts on shorting financials, and wonders if it will be a Monsanto merger Monday.
In highlights from this week's trading diary and posts, Kass discusses Joseph Papa's new gig at Valeant and how Sears is about to become a swan.
Perrigo’s (PRGO) new management faces problems at the pharmaceutical company that may not be easily fixed, according to Leerink analysts.
The company is expanding into the generics drug business.
Trade-Ideas LLC identified Perrigo (PRGO) as a pre-market laggard candidate
The drugmaker's quest to rebrand itself as a patient-first company is foundering over renewed controversy over drug pricing.
To investors' relief, Perrigo's new leadership reaffirmed the pharmaceuticals company's 2016 calendar outlook on Thursday.
Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.
Perrigo (PRGO) is scheduled to release its 2016 first quarter earnings on Thursday before the market open.
It reports tomorrow, but where will the company ultimately fall this quarter?
New Chairman and CEO Joe Papa can't stop the world from gunning for Valeant.
TheStreet's founder shares his thoughts after his one-on-one interview with Valeant's new chairman and CEO.
Cramer is remaining cautious on Valeant but is bullish on Integrated Device Technology.
This market changes on a dime, Cramer says. A market without conviction can be tricky.
The fact that Valeant will report its Q1 financials ahead of the June 10 deadline shouldn't appease investors, according to TheStreet's founder.
Despite an incredible CEO, solid businesses and a big deal with Teva, Allergan has seen its shares continue to struggle. Jim Cramer looks at why.
Jim Cramer thinks Allergan CEO Brent Saunders has put together a world class company.
New Valeant CEO and former Perrigo CEO Joseph Papa will be joining TheStreet's Jim Cramer on "Mad Money" tonight.
Cramer says he's looking forward to another week of earnings to see which bull markets are alive and well.
Three days after taking over as CEO, Papa seeks to calm investors by setting up patent access and pricing committee for drugs
TheStreet highlights 3 stocks pushing the drugs industry higher today.
Perrigo could have an oversold bounce at any time as bears turn aggressive, but nothing right now indicates a price bottom.
Jim Cramer shares his views on pajama traders and the need for new leadership in the market. Caterpillar, IBM and Coca-Cola are among the stocks discussed here.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.